Mobile

A Cancer Research UK Randomised Multicentre Phase II Trial of the DNA-hypomethylating Agent, 5-Aza-2'-deoxycytidine(Decitabine) given intravenously in Combination with Carboplatin, versus Carboplatin ...

Mise à jour : Il y a 5 ans
Référence : EUCTR2006-002324-41

A Cancer Research UK Randomised Multicentre Phase II Trial of the DNA-hypomethylating Agent, 5-Aza-2'-deoxycytidine(Decitabine) given intravenously in Combination with Carboplatin, versus Carboplatin alone given 4 weekly in patients with progressive, advanced Ovarian cancer

Femme Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To estimate the response rate of the combination of decitabine and carboplatin compared to carboplatin alone in patients with progressive advanced ovarian cancer who have previously responded to platinum based chemotherapy and who have methylated hMLH1 DNA in plasma.

Critère d'inclusion

  • Progressive, advanced ovarian cancer

Liens